First-phase viral decay rates in treatment-naive subjects initiating treatment with raltegravir (RAL) and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF): A pilot study.

Trial Profile

First-phase viral decay rates in treatment-naive subjects initiating treatment with raltegravir (RAL) and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF): A pilot study.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2015

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Nov 2015 Results from two studies (MK0518-004 and ACTG-A5248) regarding early viral kinetics were published in the AIDS.
    • 07 Nov 2012 Actual initiation date changed from Jun 2008 to May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top